LNTHHIGH SIGNALFINANCIAL10-K

Lantheus experienced a substantial deterioration in cash position alongside reduced profitability and operating performance across key metrics.

The company's cash reserves declined significantly from $912.8M to $359.1M, representing a material shift in financial position that could impact strategic flexibility and investment capacity. Combined with meaningfully lower operating income and reduced cash generation, this suggests either substantial capital deployment or operational headwinds that warrant close investor scrutiny.

Comparing 2026-02-26 vs 2025-02-26View on EDGAR →
FINANCIAL ANALYSIS

Lantheus shows broad-based financial deterioration with operating income declining meaningfully to $310.8M and operating cash flow reduced to $390.1M. The company's cash position weakened substantially while current liabilities increased to $333.4M, creating a less favorable liquidity profile. Despite total assets growing modestly to $2.2B, the overall picture suggests either significant capital investments or operational challenges that compressed profitability and cash generation.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
-60.7%
$912.8M→$359.1M

Cash declined 60.7% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Current Liabilities
Balance Sheet
+38.6%
$240.5M→$333.4M

Current liabilities surged 38.6% — significant near-term obligations; verify ability to meet short-term debt.

Current Assets
Balance Sheet
-32.2%
$1.3B→$900.0M

Current assets declined 32.2% — monitor working capital adequacy and short-term liquidity.

Operating Income
P&L
-32%
$457.0M→$310.8M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Operating Cash Flow
Cash Flow
-28.4%
$544.8M→$390.1M

Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.

Total Liabilities
Balance Sheet
+27.5%
$892.3M→$1.1B

Liabilities increased 27.5% — monitor debt-to-equity ratio and interest coverage.

Net Income
P&L
-25.2%
$312.4M→$233.6M

Net income declined 25.2% — review whether driven by operations, interest costs, or non-recurring items.

Total Assets
Balance Sheet
+12.5%
$2.0B→$2.2B

Asset base grew 12.5% — expansion through organic growth, acquisitions, or capital deployment.

Accounts Receivable
Balance Sheet
+11.6%
$321.3M→$358.6M

Receivables grew 11.6% — monitor days sales outstanding for collection efficiency.

LANGUAGE CHANGES
NEW — 2026-02-26
PRIOR — 2025-02-26
ADDED
As of February 23, 2026 the registrant had 64,605,894 shares of common stock, $0.01 par value, issued and outstanding.
Examples of forward-looking statements include statements we make relating to our outlook and expectations including, without limitation, in connection with: Continued market expansion, penetration and reimbursement for our established commercial products, particularly PYLARIFY, DEFINITY and Neuraceq, in a competitive environment, and our ability to clinically and commercially differentiate our products; Our ability to obtain U.S.
SUMMARY OF MATERIAL RISKS ASSOCIATED WITH OUR BUSINESS Our business is subject to a number of risks, including risks that may adversely affect our business, results of operations, cash flows, and prospects.
Risks Related to Our Business Operations and Financial Results Changes to management, including the recent turnover in our leadership and senior management team, could have an adverse effect on our business.
Our ability to hire or retain the number of qualified personnel, particularly scientific, medical and sales personnel, required for our business.
+7 more — sign up free →
REMOVED
As of February 20, 2025 the registrant had 68,476,575 shares of common stock, $0.01 par value, issued and outstanding.
Food and Drug Administration ( FDA ) approval for PNT2002 and PNT2003 and to be successful in the patent litigation associated with PNT2003; Our ability to successfully realize the anticipated benefits of our 2024 transactions with Perspective Therapeutics, Inc.
( Perspective ); The cost, efforts and timing for clinical development, regulatory approval, adequate coding, coverage and payment, and successful commercialization of our product candidates and new clinical applications and territories for our products, in each case, that we or our strategic partners may undertake; and Our ability to identify opportunities to collaborate with strategic partners and to acquire or in-license additional diagnostic and therapeutic product opportunities in oncology, neurology and other strategic areas and continue to grow and advance our pipeline of products.
These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in Part I, Item 1A, "Risk Factors" of this Form 10-K.
Risks Related to our Business Operations and Financial Results Our ability to hire or retain the number of qualified personnel, particularly scientific, medical and sales personnel, required for our business.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →